With Shortage Looming Large, Cipla Offers Generic Tamiflu, Relenza To U.S. Health Department
This article was originally published in PharmAsia News
MUMBAI - Known for supplying low-priced anti-retroviral cocktail therapy to frontline African nations to combat the spread of HIV/AIDS, Cipla - India's largest drug maker by market share - is in discussions with U.S. health agencies to boost production of antiviral oseltamivir, the generic for Roche's Tamiflu for treating the rapidly spreading H1N1 virus
You may also be interested in...
Roche, GSK could benefit from influenza drug stockpiling in Asia as H7N9 strain of avian flu hits headlines, despite public health official calls of overreaction.
Complex Regulatory Pathways Pose Hurdles For Effective CLs; Cipla’s Hamied Calls For Automatic Licensing Rights
Cipla Chairman Yusuf Hamied has proposed an automatic licensing mechanism that could avoid the need for a compulsory license and would allow generic firms to launch patented drugs via an automatic route.
MUMBAI - India's health ministry has gone into hyperactive mode to combat the spread of the A/H1N1 influenza virus. The disease has claimed 14 lives over the last five days, while close to 1,000 more people tested positive and were treated in government-run hospitals